Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Minnesota
Clinical trial register · United States · industry-sponsored

Clinical Trials in Minnesota, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9118 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 06 Oct 2026, 03:16 UTC
9118
Studies in scope
industry-sponsored, all four open statuses
4945
Recruiting now
open to new participants
2189
Lead sponsors
across recruiting studies
Top states
California 232 Florida 174 Arizona 114 Illinois 110 Georgia 105
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca36 Novartis Pharmaceuticals23 AbbVie19 Eli Lilly and Company18 Bristol-Myers Squibb16 Clear sponsor filter
State
California232 Florida174 Arizona114 Illinois110 Georgia105
All 48 states
Target enrolment
to

Trials with a site in Minnesota

36 of 9118 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment
NCT07691970Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus
DrugAnifrolumab
AstraZeneca
Phase 3
1,072
Arizona, California, Florida, Illinois, Michigan, Minnesota, Nebraska, New York
2026-08-31
Not yet open
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
NCT07735637Newly Diagnosed Multiple Myeloma (NDMM)
DrugsASCT·AZD0120·Melphalan·Lenalidomide
AstraZeneca
Phase 3
750
Florida, Georgia, Illinois, Michigan, Minnesota, Ohio, Texas, Washington
2026-08-25
Recruiting
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin
NCT07662135Type 2 Diabetes Mellitus, Type 2 Diabetes With Chronic Kidney Disease
DrugElecoglipron
AstraZeneca
Phase 3
900
Arizona, California, Florida, Illinois, Massachusetts, Michigan, Minnesota, Missouri
2026-07-06
Recruiting
Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer
NCT07590934Metastatic Prostate Cancer
DrugsAZD2287·FPI-2265·Palacaparib·Docetaxel
AstraZeneca
Phase 1/2
152
California, Florida, Louisiana, Minnesota, Nebraska, New York, Oregon, Texas
2026-06-03
Recruiting
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
NCT06996782Advanced or Metastatic Non-small Cell Lung Cancer
DrugsRamucirumab·Rilvegostomig·Nab-paclitaxel·Pemetrexed
AstraZeneca
Phase 1/2
152
Arizona, California, Florida, Maryland, Michigan, Minnesota, Ohio, Rhode Island
2025-11-24
Recruiting
Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney Disease
NCT07228364Autosomal Dominant Polycystic Kidney Disease
DrugAZD1613
AstraZeneca
Phase 1
40
Alabama, California, Florida, Kansas, Maryland, Minnesota, Texas
2025-11-10
Recruiting
A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization
NCT07088926Bronchiectasis With Pseudomonas Aeruginosa Colonization
DrugAZD0292
AstraZeneca
Phase 2
435
California, Colorado, District of Columbia, Florida, Georgia, Kansas, Michigan, Minnesota
2025-11-06
Recruiting
A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
NCT07123454B-cell Non-Hodgkin Lymphoma
AstraZeneca
Phase 1/2
91
California, Florida, Minnesota, New York, Ohio, South Carolina, Tennessee
2025-09-24
Not yet open
LTFU for All Cell and Gene Therapy Studies
NCT06194461Hepatocellular Carcinoma, Prostate Cancer
DrugsAZD0754·AZD5851
AstraZeneca
Observational
64
Arizona, California, District of Columbia, Florida, Georgia, Kansas, Minnesota, Missouri
2025-09-17
Recruiting
A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism
NCT07007793Primary Hyperaldosteronism
DrugBaxdrostat
AstraZeneca
Phase 3
250
California, Connecticut, Illinois, Maryland, Massachusetts, Michigan, Minnesota, Mississippi
2025-08-07
Recruiting
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
NCT07073547Multiple Myeloma
DrugAZD0120
AstraZeneca
Phase 1
40
Arizona, California, Colorado, Florida, Georgia, Iowa, Minnesota, Missouri
2025-07-31
Recruiting
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4248 in Healthy Participants and Participants With Chronic Kidney Disease and Type 2 Diabetes and to Assess Home Measurements of Creatinine in a Non Interventional Cohort
NCT07024823Chronic Kidney Disease
AstraZeneca
Phase 1
124
California, Illinois, Michigan, Minnesota, Texas
2025-06-09
Recruiting
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
NCT06792695Metastatic Colorectal Cancer
DrugsFOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan)·Volrustomig·Bevacizumab
AstraZeneca
Phase 2
80
Arizona, California, District of Columbia, Illinois, Maryland, Massachusetts, Minnesota, New Jersey
2025-03-12
Recruiting
A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT06879041Metastatic Castration-Resistant Prostate Cancer
DrugAZD2287
AstraZeneca
Phase 1
136
California, Florida, Illinois, Louisiana, Massachusetts, Minnesota, Nebraska, New York
2025-03-10
Recruiting
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
NCT06526793B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL)
DrugSurovatamig
AstraZeneca
Phase 2
270
Arizona, California, Florida, Illinois, Iowa, Kansas, Minnesota, Missouri
2024-11-27
Recruiting
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
NCT06542250B-cell Malignancies
DrugAZD5492
AstraZeneca
Phase 1/2
174
California, Massachusetts, Minnesota, New Jersey, New York, North Carolina, Texas, Washington
2024-09-18
Recruiting
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
NCT06465810Transthyretin Amyloidosis, ATTR-CM, ATTRv-PN, ATTR
AstraZeneca
Observational
1,850
California, Connecticut, District of Columbia, Illinois, Indiana, Maryland, Massachusetts, Minnesota
2024-06-25
Active, closed
Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care
NCT06422689Asthma
AstraZeneca
Phase 4
1,511
California, Kentucky, Massachusetts, Michigan, Minnesota, North Carolina, Pennsylvania, Texas
2024-05-10
Recruiting
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
NCT05835310Systemic Lupus Erythematosus
DrugAnifrolumab
AstraZeneca
Phase 3
100
Arizona, California, District of Columbia, Illinois, Louisiana, Maryland, Minnesota, New York
2024-03-14
Active, closed
A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma
NCT06084884Hepatocellular Carcinoma
DrugAZD5851
AstraZeneca
Phase 1/2
94
Arizona, California, District of Columbia, Florida, Georgia, Kansas, Minnesota, New Jersey
2023-12-14
Active, closed
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
NCT06097728Unresectable Pleural Mesothelioma
DrugsVolrustomig·Yervoy·Paraplatin·Ipilimumab
AstraZeneca
Phase 3
863
California, Colorado, Florida, Georgia, Illinois, Minnesota, Missouri, New York
2023-11-09
Recruiting
OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis
NCT06355934ATTR Amyloidosis
AstraZeneca
Observational
52,121
Minnesota
2023-08-21
Recruiting
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
NCT06005493Gastric Cancer, Gastro-esophageal Junction Cancer, Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma
DrugRilvegostomig
AstraZeneca
Phase 1/2
392
Florida, Minnesota, New York
2023-07-11
Active, closed
A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT05057494Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
DrugsAcalabrutinib·Obinutuzumab·Venetoclax
AstraZeneca
Phase 3
607
Arizona, California, Colorado, Florida, Massachusetts, Minnesota, Missouri, New York
2022-09-12
Active, closed
Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT05348577Prostate Cancer
DrugsCapivasertib·Docetaxel
AstraZeneca
Phase 3
1,035
Arizona, California, Colorado, Maryland, Minnesota, New Jersey, New York, Ohio
2022-03-25
Active, closed
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
NCT05113251Breast Neoplasms, Breast Cancer, HER2-positive Early Breast Cancer
DrugsHerzuma·Perjeta·Herceptin·Adriamycin
AstraZeneca
Phase 3
927
Arkansas, California, Connecticut, Indiana, Kentucky, Louisiana, Minnesota, Nevada
2021-10-25
Active, closed
A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC
NCT04995523Non-Small-Cell Lung Carcinoma
DrugRilvegostomig
AstraZeneca
Phase 1/2
212
Illinois, Minnesota, Virginia
2021-09-14
Active, closed
Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas
NCT05101148Neurofibromatosis Type 1
DrugSelumetinib
AstraZeneca
Phase 1
24
Minnesota, Ohio
2021-07-21
Active, closed
Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer
NCT04590963Squamous Cell Carcinoma of the Head and Neck
DrugsMonalizumab·Erbitux·Cetuximab
AstraZeneca
Phase 3
370
Arizona, Illinois, Kansas, Massachusetts, Michigan, Minnesota, Missouri, Nevada
2020-10-02
Active, closed
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
NCT04421963Ovarian Cancer, Breast Cancer
DrugOlaparib
AstraZeneca
Phase 3
185
Florida, Maryland, Michigan, Minnesota, New Jersey, New York, Pennsylvania, Rhode Island
2020-08-04
Active, closed
Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer
NCT04305496Locally Advanced (Inoperable) or Metastatic Breast Cancer
DrugsCapivasertib·Fulvestrant
AstraZeneca
Phase 3
818
Arizona, California, Florida, Kansas, Maryland, Massachusetts, Minnesota, Missouri
2020-04-16
Active, closed
Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab.
NCT04157348Eosinophilic Granulomatous Vasculitis
DrugsBenralizumab·Mepolizumab
AstraZeneca
Phase 3
140
Colorado, Michigan, Minnesota, New Mexico, New York, Pennsylvania, Texas, Washington
2019-10-29
Active, closed
Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib
NCT03778229Carcinoma
DrugsSavolitinib·Osimertinib
AstraZeneca
Phase 2
367
California, District of Columbia, Maryland, Massachusetts, Minnesota, New York, Pennsylvania, Washington
2019-01-09
Active, closed
A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma
NCT03778957Hepatocellular Carcinoma
DrugsAvastin·Durvalumab·Bevacizumab
AstraZeneca
Phase 3
724
California, District of Columbia, Florida, Hawaii, Illinois, Louisiana, Michigan, Minnesota
2018-11-30
Active, closed
Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
NCT03298451Hepatocellular Carcinoma
DrugsSorafenib·Tremelimumab·Durvalumab
AstraZeneca
Phase 3
1,324
California, District of Columbia, Florida, Kansas, Maryland, Michigan, Minnesota, New York
2017-10-11
Active, closed
Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)
NCT02453282Non-Small-Cell Lung Carcinoma NSCLC
DrugsTremelimumab·Durvalumab·Pemetrexed·Gemcitabine
AstraZeneca
Phase 3
1,118
Arizona, California, Connecticut, Florida, Georgia, Hawaii, Maryland, Minnesota
2015-07-21
Rows per page Showing 1–36 of 36
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 7 October 2026. https://priyalifescience.com/clinical-trials-usa/state/minnesota

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,118 studies in total at the last sync on 06 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 36 of those studies with a site in Minnesota that also match the filters currently applied.

How many clinical trials are recruiting in Minnesota?

18 of the 36 studies on this page are recruiting new participants as of the 06 Oct 2026, 03:16 UTC sync. A further 2 have not yet opened recruitment, 16 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Minnesota), 36 studies
PhaseStudiesRecruitingShare
Phase 316444.4%
Phase 1/27519.4%
Phase 15413.9%
Phase 24311.1%
Observational328.3%
Phase 4102.8%

Most active sponsors

Lead sponsors with the most studies (Minnesota)
Lead sponsorStudiesRecruiting
AstraZeneca3618
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.